Our top pick for
Building a portfolio
Nanobiotix S.A is a biotechnology business based in the US. Nanobiotix S-A shares (NBTX) are listed on the NASDAQ and all prices are listed in US Dollars. Nanobiotix S-A employs 88 staff and has a trailing 12-month revenue of around USD$2.5 million.
|52-week range||USD$13.5 - USD$21.55|
|50-day moving average||USD$15.8468|
|200-day moving average||USD$16.983|
|Wall St. target price||USD$24.72|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$2.5 million|
|Gross profit TTM||USD$2.5 million|
|Return on assets TTM||-23.94%|
|Return on equity TTM||-97.99%|
|Market capitalisation||USD$600.2 million|
TTM: trailing 12 months
There are currently 6,870 Nanobiotix S-A shares held short by investors – that's known as Nanobiotix S-A's "short interest". This figure is 28.9% down from 9,667 last month.
There are a few different ways that this level of interest in shorting Nanobiotix S-A shares can be evaluated.
Nanobiotix S-A's "short interest ratio" (SIR) is the quantity of Nanobiotix S-A shares currently shorted divided by the average quantity of Nanobiotix S-A shares traded daily (recently around 8696.2025316456). Nanobiotix S-A's SIR currently stands at 0.79. In other words for every 100,000 Nanobiotix S-A shares traded daily on the market, roughly 790 shares are currently held short.
To gain some more context, you can compare Nanobiotix S-A's short interest ratio against those of similar companies.
However Nanobiotix S-A's short interest can also be evaluated against the total number of Nanobiotix S-A shares, or, against the total number of tradable Nanobiotix S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nanobiotix S-A's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Nanobiotix S-A shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Nanobiotix S-A shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Nanobiotix S-A.
Find out more about how you can short Nanobiotix S-A stock.
We're not expecting Nanobiotix S-A to pay a dividend over the next 12 months.
Over the last 12 months, Nanobiotix S-A's shares have ranged in value from as little as $13.5 up to $21.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nanobiotix S-A's is 2.1611. This would suggest that Nanobiotix S-A's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Nanobiotix S-A's beta into context you can compare it against those of similar companies.
Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.